4,060 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Purchased by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,060 shares of the medical instruments supplier’s stock, valued at approximately $377,000.

Several other institutional investors have also modified their holdings of LMAT. Summit Global Investments lifted its stake in shares of LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock worth $575,000 after acquiring an additional 146 shares during the last quarter. Shaker Investments LLC OH lifted its position in shares of LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock worth $1,138,000 after purchasing an additional 175 shares during the last quarter. NBC Securities Inc. grew its holdings in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares during the last quarter. Finally, nVerses Capital LLC increased its stake in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the period. 84.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on LMAT. Oppenheimer restated an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Finally, JMP Securities upped their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.57.

Insiders Place Their Bets

In related news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

LMAT stock opened at $105.02 on Wednesday. The firm has a 50-day simple moving average of $96.07 and a two-hundred day simple moving average of $88.41. LeMaitre Vascular, Inc. has a one year low of $52.55 and a one year high of $109.58. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of 57.39, a PEG ratio of 2.58 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the firm earned $0.33 earnings per share. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.